{"title":"一种新的贝叶斯无分布生存分析。","authors":"Richard A Chechile, Daniel H Barch","doi":"10.1002/sim.70736","DOIUrl":null,"url":null,"abstract":"<p><p>A new Bayesian distribution-free medical survivor analysis is presented that strictly avoids using right-tail censored data. The Bayesian procedure is focused on two population parameters called <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> and <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> , which are separate metrics of a treatment difference between the two conditions. The <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> parameter is the proportion of failures that are from the Control condition, and the <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> parameter is a stochastic difference measure associated with longer survival time before a failure for the patients in the Experimental condition. Point and interval estimates along with a Bayes factor are provided for both parameters. Software is provided for implementing the Bayesian analysis. Monte Carlo simulations are also developed to study the interplay between the stop-testing time used in survival analysis with other variables such as effect size and sample size. The simulations also provide information that enable an approach to survival analysis where there is an early decision about the relative effectiveness of the treatments that is based on the Bayes factor value associated with the <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> statistic. This decision can be made when there is a high proportion of right-tail censored data. In the limit of times so long that there are all failures-thus no right-tail censoring-the <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> metric is not informative, but the <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> metric is still a valid measure of the stochastic difference in failure times between the two conditions.</p>","PeriodicalId":21879,"journal":{"name":"Statistics in Medicine","volume":"45 20-22","pages":"e70736"},"PeriodicalIF":2.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Novel Bayesian Distribution-Free Survival Analysis.\",\"authors\":\"Richard A Chechile, Daniel H Barch\",\"doi\":\"10.1002/sim.70736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A new Bayesian distribution-free medical survivor analysis is presented that strictly avoids using right-tail censored data. The Bayesian procedure is focused on two population parameters called <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> and <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> , which are separate metrics of a treatment difference between the two conditions. The <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> parameter is the proportion of failures that are from the Control condition, and the <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> parameter is a stochastic difference measure associated with longer survival time before a failure for the patients in the Experimental condition. Point and interval estimates along with a Bayes factor are provided for both parameters. Software is provided for implementing the Bayesian analysis. Monte Carlo simulations are also developed to study the interplay between the stop-testing time used in survival analysis with other variables such as effect size and sample size. The simulations also provide information that enable an approach to survival analysis where there is an early decision about the relative effectiveness of the treatments that is based on the Bayes factor value associated with the <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> statistic. This decision can be made when there is a high proportion of right-tail censored data. In the limit of times so long that there are all failures-thus no right-tail censoring-the <math> <mrow> <msub><mrow><mi>ϕ</mi></mrow> <mrow><mi>f</mi> <mi>c</mi></mrow> </msub> </mrow> </math> metric is not informative, but the <math> <mrow> <msub><mrow><mi>Ω</mi></mrow> <mrow><mi>E</mi></mrow> </msub> </mrow> </math> metric is still a valid measure of the stochastic difference in failure times between the two conditions.</p>\",\"PeriodicalId\":21879,\"journal\":{\"name\":\"Statistics in Medicine\",\"volume\":\"45 20-22\",\"pages\":\"e70736\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2026-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Statistics in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/sim.70736\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MATHEMATICAL & COMPUTATIONAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/sim.70736","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
提出了一种严格避免使用右尾截尾数据的无贝叶斯医学生存者分析方法。贝叶斯过程的重点是两个称为φ f c和Ω E的总体参数,这是两个条件之间处理差异的单独指标。其中φ f c参数是来自控制条件的失败的比例,Ω E参数是一个随机差分测量,与实验条件下患者在失败前的较长生存时间相关。为这两个参数提供了点和区间估计以及贝叶斯因子。提供了实现贝叶斯分析的软件。蒙特卡罗模拟也用于研究生存分析中使用的停止测试时间与其他变量(如效应大小和样本量)之间的相互作用。模拟还提供了信息,使生存分析的方法,其中有一个关于治疗的相对有效性的早期决定,这是基于与φ - f统计相关的贝叶斯因子值。当右尾截尾数据的比例很高时,可以做出这个决定。在有限的时间内,所有的故障都存在——因此没有右尾审查——φ f度量是没有信息的,但是Ω E度量仍然是两个条件之间故障时间随机差异的有效度量。
A Novel Bayesian Distribution-Free Survival Analysis.
A new Bayesian distribution-free medical survivor analysis is presented that strictly avoids using right-tail censored data. The Bayesian procedure is focused on two population parameters called and , which are separate metrics of a treatment difference between the two conditions. The parameter is the proportion of failures that are from the Control condition, and the parameter is a stochastic difference measure associated with longer survival time before a failure for the patients in the Experimental condition. Point and interval estimates along with a Bayes factor are provided for both parameters. Software is provided for implementing the Bayesian analysis. Monte Carlo simulations are also developed to study the interplay between the stop-testing time used in survival analysis with other variables such as effect size and sample size. The simulations also provide information that enable an approach to survival analysis where there is an early decision about the relative effectiveness of the treatments that is based on the Bayes factor value associated with the statistic. This decision can be made when there is a high proportion of right-tail censored data. In the limit of times so long that there are all failures-thus no right-tail censoring-the metric is not informative, but the metric is still a valid measure of the stochastic difference in failure times between the two conditions.
期刊介绍:
The journal aims to influence practice in medicine and its associated sciences through the publication of papers on statistical and other quantitative methods. Papers will explain new methods and demonstrate their application, preferably through a substantive, real, motivating example or a comprehensive evaluation based on an illustrative example. Alternatively, papers will report on case-studies where creative use or technical generalizations of established methodology is directed towards a substantive application. Reviews of, and tutorials on, general topics relevant to the application of statistics to medicine will also be published. The main criteria for publication are appropriateness of the statistical methods to a particular medical problem and clarity of exposition. Papers with primarily mathematical content will be excluded. The journal aims to enhance communication between statisticians, clinicians and medical researchers.